Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16250030rdf:typepubmed:Citationlld:pubmed
pubmed-article:16250030lifeskim:mentionsumls-concept:C0026650lld:lifeskim
pubmed-article:16250030lifeskim:mentionsumls-concept:C0030567lld:lifeskim
pubmed-article:16250030lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:16250030lifeskim:mentionsumls-concept:C0442592lld:lifeskim
pubmed-article:16250030lifeskim:mentionsumls-concept:C1425650lld:lifeskim
pubmed-article:16250030lifeskim:mentionsumls-concept:C0376249lld:lifeskim
pubmed-article:16250030lifeskim:mentionsumls-concept:C0041703lld:lifeskim
pubmed-article:16250030lifeskim:mentionsumls-concept:C0205214lld:lifeskim
pubmed-article:16250030pubmed:issue4lld:pubmed
pubmed-article:16250030pubmed:dateCreated2006-4-17lld:pubmed
pubmed-article:16250030pubmed:abstractTextThe G2019S mutation in the LRRK2 gene is reportedly a common cause of familial Parkinson's disease (PD) and may also have a significant role in nonfamilial PD. The objective of this study was to assess mutation carrier frequency in PD patients from movement disorder clinics in the United States, stratified by family history, age at onset, and geography; to determine carrier frequency in a large and well-characterized control population; to examine segregation of mutation in families of patients; and to correlate genotype with clinical phenotype. One thousand four hundred twenty-five unrelated PD patients from movement disorder clinics in Oregon, Washington, and New York and 1,647 unrelated controls were studied. The G2019S mutation was detected using a TaqMan assay and verified by sequencing. Eighteen of 1,425 patients and one of 1,647 controls had the mutation. Carrier frequency (+/- 2SE) in patients was 0.013 +/- 0.006 overall, 0.030 +/- 0.019 in familial PD, 0.007 +/- 0.005 in nonfamilial PD, 0.016 +/- 0.013 in early-onset PD, and 0.012 +/- 0.007 in late-onset PD. Geographic differences were insignificant. Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date.lld:pubmed
pubmed-article:16250030pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250030pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250030pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250030pubmed:languageenglld:pubmed
pubmed-article:16250030pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250030pubmed:citationSubsetIMlld:pubmed
pubmed-article:16250030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250030pubmed:statusMEDLINElld:pubmed
pubmed-article:16250030pubmed:monthAprlld:pubmed
pubmed-article:16250030pubmed:issn0885-3185lld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:NuttJohn GJGlld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:PayamiHaydehHlld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:FactorStewart...lld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:ZabetianCyrus...lld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:SamiiAliAlld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:KramerPatrici...lld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:BirdTom DTDlld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:KayDenise MDMlld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:HigginsDonald...lld:pubmed
pubmed-article:16250030pubmed:authorpubmed-author:GriffithAlida...lld:pubmed
pubmed-article:16250030pubmed:copyrightInfoCopyright 2005 Movement Disorder Society.lld:pubmed
pubmed-article:16250030pubmed:issnTypePrintlld:pubmed
pubmed-article:16250030pubmed:volume21lld:pubmed
pubmed-article:16250030pubmed:ownerNLMlld:pubmed
pubmed-article:16250030pubmed:authorsCompleteYlld:pubmed
pubmed-article:16250030pubmed:pagination519-23lld:pubmed
pubmed-article:16250030pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:meshHeadingpubmed-meshheading:16250030...lld:pubmed
pubmed-article:16250030pubmed:year2006lld:pubmed
pubmed-article:16250030pubmed:articleTitleParkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.lld:pubmed
pubmed-article:16250030pubmed:affiliationGenomics Institute, Wadsworth Center, New York State Department of Health, Albany, 12201, USA.lld:pubmed
pubmed-article:16250030pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16250030pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16250030pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16250030pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
entrez-gene:120892entrezgene:pubmedpubmed-article:16250030lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16250030lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16250030lld:entrezgene
lhgdn:association:23325lhgdn:found_inpubmed-article:16250030lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16250030lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16250030lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16250030lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16250030lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16250030lld:pubmed